1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6354D01FDFDA0439485256DDA0056B53B
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/managing-market-planning-for-new-oncology-products?opendocument
18
19OpenForm&Seq=5&PLCode=1&Category=Sales@@And@@Marketing&Criteria=Pharmaceutical
2018.206.194.83
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » »

Managing Market Planning for New Oncology Products

Managing Market Planning for New Oncology Products

ID: PSM-205


Features:

4 Info Graphics

3 Data Graphics

11 Metrics

6 Narratives

4 Best Practices


Pages: 14


Published: Pre-2014


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Understand how leading pharmaceutical companies effectively manage market planning for oncology products during Phase II and Phase III. Insights from six companies compiled from a survey and interviews by Best Practices, LLC serve as an excellence benchmark against which companies can compare their own operations.

Industries Profiled:
Market Research; Manufacturing; Medical Device; Pharmaceutical; Financial Services; Service; Retail; Research; Computer Software; Diagnostic; Health Care; Transportation; Biotech; Clinical Research; Consulting; Distribution; Insurance; Hospitality; Telecommunications; Technology; Professional Services; High Tech; Automobile; Utilities; Energy; Consumer Products; Chemical; Medical; Electronics; Laboratories; Biopharmaceutical; Banking; Computers; Entertainment; Internet; Computer Hardware; Aerospace; Academic; Media; Education; Newspapers; Government; Shipping; Science; Office Supplies; Marketing; Office Equipment; Cable; Advertising; Defense; Military; Diversified; Sports; Technology; Public Relations; Multiple; Communications; Logistics; Publishing; Real Estate; Construction; Architecture; Engineering; Aviation; Legal; Test Industry; Non-Profit; Business; Orthopaedics


Companies Profiled:

Study Snapshot

This 13-slide Executive Presentation reveals how six leading pharmaceutical companies effectively manage market planning for oncology products during Phase II and Phase III clinical trials.

Drawn from primary interviews with oncology product managers, the study highlights the following key aspects of oncology product marketing:

  • effective advisory board approaches used by benchmarking companies
  • the three distinct approaches in registering and launching multiple targeted therapies 
  • new clinical trial endpoints used by benchmarking companies
  • critical factors that affect a product's ability to quickly reach peak sales

Overall, the presentation includes: 
  • 6 Information Graphics
  • 2 Data Graphics
  • 9 Manager or Executive Narratives
  • 7 Metrics

Four key findings summarize the insights drawn from benchmark companies' new oncology product market planning programs.

Key Findings

Best Practices, LLC identified and profiled key findings that summarize how leading pharmaceutical companies effectively manage market planning for new oncology products.  From a survey and executive interviews, several key findings emerged. A sample of one key finding follows: 

  • For oncology products, benchmark partner companies use significantly more research-focused thought leaders for advisory boards in early stages.  The advisory boards are usually comprised of seven to ten physicians, and companies increase the amount of meetings with them as launch nears.
Table of Contents

Project Overview
  • Benchmark Class
  • Key Findings
  • Thought Leader Mix for Advisory Boards
  • Advisory Board Size and Structure
  • Advisory Board Meeting & Frequency
  • Advisory Board Objectives
  • Registration and Launch Strategies
  • Novel Clinical Endpoints
  • Time to Peak Sales
  • Lessons Learned